EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Assessing clinical meaningfulness in clinical trials for Alzheimer's disease: A U.S. regulatory perspective

Teresa Buracchio iD, Michelle Campbell, Kevin Krudys

Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2025-04 · 11 (2)

DOI: 10.1002/trc2.70113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia: Translational Research & Clinical Interventions, online erschienen am 04.06.2025. Verfasst von Teresa Buracchio und 2 weiteren Autor:innen. Beteiligte Einrichtung: Office of Neuroscience Office of New Drugs Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the context of recent approvals of amyloid‐directed monoclonal antibodies for the treatment of Alzheimer's disease (AD) by the United States (U.S.) Food and Drug administration (FDA), there has been much public discussion regarding the meaningfulness of the treatment effects demonstrated with these drugs in clinical trials. There are a variety of regulatory approaches to evaluate how results on a clinical endpoint reflect a meaningful effect of an intervention, including qualitative and quantitative methodologies. This article will discuss regulatory considerations for clinical benefit across the stages of AD, approaches to the assessment of clinical meaningfulness in clinical trials, and FDA's assessment of clinical benefit in the recent traditional approvals of amyloid‐directed monoclonal antibodies for the treatment of AD. Highlights Assessment of clinical benefit will depend on the stage of Alzheimer's disease (AD) being studied, the clinical symptoms or findings that occur at that stage of disease, and the mechanism of the drug and its anticipated effects. It is critical to obtain input from patients and caregivers with lived experience to understand their perspectives on clinical benefit. The Food and Drug Administration (FDA) encourages the use of clinically meaningful within‐patient change, which captures the assessment of improvement or decline based on the perspective of the individual patient, to assess meaningful score differences.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseclinical meaningfulnessclinical outcome assessmentclinical trialsdrug development

Autor:innen und Institutionen

  • Office of Neuroscience Office of New Drugs Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA.

ORCID-Profile: Teresa Buracchio

Zitieren

APA

Buracchio, T., Campbell, M., & Krudys, K. (2025). Assessing clinical meaningfulness in clinical trials for Alzheimer's disease: A U.S. regulatory perspective. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 11(2). https://doi.org/10.1002/trc2.70113

Vancouver

Buracchio T, Campbell M, Krudys K. Assessing clinical meaningfulness in clinical trials for Alzheimer's disease: A U.S. regulatory perspective. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2025;11(2). doi:10.1002/trc2.70113

BibTeX
@article{Buracchio2025,
  author = {Buracchio, Teresa and Campbell, Michelle and Krudys, Kevin},
  title = {Assessing clinical meaningfulness in clinical trials for Alzheimer's disease: A U.S. regulatory perspective},
  journal = {Alzheimer's & Dementia: Translational Research & Clinical Interventions},
  year = {2025},
  volume = {11},
  number = {2},
  doi = {10.1002/trc2.70113}
}
Kostenlos starten →